Cartesian Therapeutics (RNAC) Current Assets (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Current Assets data on file, last reported at $122.0 million in Q1 2026.

• Current Assets for Q1 2026 came in at $122.0 million, down 34.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $122.0 million (down 34.08% YoY), and the FY2025 annual result was $129.3 million, down 40.32% from the prior year.
• Current Assets retreated to $122.0 million in Q1 2026 per RNAC's latest filing, from $129.3 million in the prior quarter.
• Over five years, Current Assets peaked at $229.1 million in Q3 2024 and troughed at $89.9 million in Q3 2023.
• A 5-year average of $145.9 million and a median of $138.4 million in 2023 frame the typical range for Current Assets.
• The sharpest annual moves came in 2023 and 2024: Current Assets sank 43.72% in 2023, then jumped 154.97% in 2024.
• A 5-year view of Current Assets shows it stood at $148.1 million in 2022, then tumbled by 38.75% to $90.7 million in 2023, then jumped by 138.76% to $216.6 million in 2024, then sank by 40.32% to $129.3 million in 2025, then fell by 5.6% to $122.0 million in 2026.
• Business Quant data shows RNAC's Current Assets at $122.0 million in Q1 2026, $129.3 million in Q4 2025, and $147.3 million in Q3 2025.